newsfilter
← Latest News
GlobeNewswire·

AVEO Oncology Reports Full Year and Fourth Quarter 2021 Financial Results

– Total 2021 Net Revenue of $42.3 Million – – FOTIVDA® (tivozanib) U.S. Net Product Revenue of $38.9 Million since March 22, 2021 – – FOTIVDA U.S. Net Product Revenue of $16.8 Million for 4Q 2021, Driven by a 26% Increase in Prescription